The zebrafish model is an emerging system for the study of neuromuscular disorders. In the study of neuromuscular diseases, the integrity of the muscle membrane is a critical disease determinant. To date, numerous neuromuscular conditions display degenerating muscle fibers with abnormal membrane integrity; this is most commonly observed in muscular dystrophies. Evans Blue Dye (EBD) is a vital, cell permeable dye that is rapidly taken into degenerating, damaged, or apoptotic cells; in contrast, it is not taken up by cells with an intact membrane. EBD injection is commonly employed to ascertain muscle integrity in mouse models of neuromuscular diseases. However, such EBD experiments require muscle dissection and/or sectioning prior to analysis. In contrast, EBD uptake in zebrafish is visualized in live, intact preparations. Here, we demonstrate a simple and straightforward methodology for performing EBD injections and analysis in live zebrafish. In addition, we demonstrate a co-injection strategy to increase efficacy of EBD analysis. Overall, this video article provides an outline to perform EBD injection and characterization in zebrafish models of neuromuscular disease.
Introduction
Muscular dystrophies constitute a group of prevalent and heterogeneous human muscle diseases with specific histopathological features 1, 2 . Symptoms typically associated with this devastating group of diseases include muscle weakness, muscle degeneration, loss of motility, and early mortality 1, 3 . The primary pathomechanisms of muscular dystrophies are the loss of proteins that stabilize the sarcolemma, anchor transmembrane complexes, and mediate cell signaling across the membrane [4] [5] [6] . For example, complete loss of the protein dystrophin, a primary scaffold protein of the dystrophin-glycoprotein complex, results in destabilization of the muscle membrane in Duchenne muscular dystrophy 7 . Due to the fact that most muscular dystrophies result from mutations in proteins that participate in the link between the extracellular matrix and the sarcolemmal cytoskeleton, a common observation at the cellular level is the loss of sacrolemmal integrity 8, 9 . This understanding of the primary pathomechanism(s) associated with muscular dystrophies is the product of numerous years of research employing animal model systems 2, [10] [11] [12] [13] [14] [15] . However, despite advances in the field, there are still limited therapeutic options for treatment or management of the range of dystrophy subtypes. This limitation of viable therapies is due to several key factors: 1) the difficulty of gene therapy strategies, 2) a high frequency of de-novo disease cases and the corresponding lack of translatable animal models, and 3) the lack of rigorous strategies to test the physiological consequences of putative therapeutic agents with clear and reproducible outcome measures.
To overcome some of these limitations, numerous labs including our own are employing zebrafish as a system to model and study human neuromuscular diseases 2 . To date, zebrafish have proven a valuable tool in disease research. The zebrafish model has been used to identify and validate novel human disease causing mutations 16, 17 , elucidate uncharacterized disease causing mechanisms 17, 18 , and identify novel therapeutic strategies 12, 19 . These advances were made, in part, by the canonical strengths of the zebrafish system such as their optical clarity, ease of genetic manipulation, and ability to breed in large numbers 20 . Zebrafish have additionally proven amendable to large-scale drug screens 21 , a valuable method for the identification of novel therapeutics [22] [23] [24] . Regarding muscle disease research, these strengths are complemented by the ability to isolate single zebrafish skeletal muscle fibers via dissociation 25 and by the ability to examine myofiber organization in vivo using the optical phenomenon called birefringence 26 , which collectively allows for rapid determination of macroscopic muscle integrity. Regardless of these available utilities, further tool development is continuously required to advance investigation.
We, and others, have adapted a protocol for EBD injection and analysis in the zebrafish model. EBD is a vital, cell permeable dye that is taken up by damaged, degenerating, or apoptotic cells and then visualized under fluorescence 27 . To date, EBD analysis has extensively been used to analyze muscle membrane integrity in mouse models of skeletal muscle and heart diseases 1. After the desired number of larvae are injected, return injected larvae to 1X Ringer's solution without tricaine in 100 mm dishes. 2. Keep dishes wrapped in aluminum foil. Note: Keeping injected larvae in the dark significantly increases survival rates and ensures the greatest consistency in signal strength. Wrapping in aluminum foil is especially important for the period of time that the larvae are outside of the incubator. 3. Allow larvae to incubate at 28.5
°C for 4-6 hr to ensure sufficient EBD uptake.
6. Visualization of EBD in the Muscle (Time: Dependent on number of larvae injecting and type of microscopy, estimated 0.5-3 hr)
1. Prior to imaging, anesthetize the larvae with 0.04% tricaine to prevent movement. 2. View larvae under red fluorescence to determine if EBD uptake is occurring in the skeletal muscle (Figure 3 ).
Representative Results
The EBD injection mix was injected into the CCV of sapje homozygous mutants and wild-type siblings at 3 dpf. Injections that filled the heart chambers ( Figure 1B) were then analyzed for successful injection by visualizing FITC-dextran in the vasculature under green fluorescence (Figure 2) .
After a 4 hr incubation period, EBD uptake was examined at the somite level using fluorescence microscopy. Wild type siblings exhibited no EBD fluorescence within any visible muscle fibers ( Figure 3A) , whereas the sapje homozygous mutants showed EBD uptake, indicating damage to the muscle membrane 15 ( Figure 3B ). 
(B)
Sapje homozygous mutant with EBD fluorescence within multiple muscle fibers (arrows). All larvae were injected with the EBD injection mix and analyzed after a 4 hr incubation period at 3 dpf. Siblings and mutants were sorted by muscle fiber detachment prior to CCV injection. Please click here to view a larger version of this figure.
Discussion
Zebrafish are emerging as a powerful tool for the study of neuromuscular disease 2, 29 . To date, the zebrafish system has been used to validate new muscle disease-causing mutations 16, 17, 30 , elucidate novel pathomechanisms 18 , and identify potentially new therapeutic drugs 12, 24 . These collective efforts have established the utility of the zebrafish to model human neuromuscular diseases. However, despite the advances made with zebrafish and mammalian models, there are limited treatment options for patients within the wide spectrum of neuromuscular conditions. Therefore, a high demand exists for therapy development for this group of devastating diseases. Paralleling this demand for therapeutics is the corresponding need for ongoing experimental innovation, as well as rigorous analysis to verify new animal models and putative therapeutic strategies.
. Most notably, EBD is used extensively in mouse models of various muscular dystrophy subtypes to show the severity of muscle membrane instability and damage 8 . The use of EBD to reveal muscle membrane damage is a supportive parameter establishing similarities of the animal model to the human disease state 9 . The power of EBD in mouse has led several labs, including our own, to develop and apply EBD to zebrafish models of neuromuscular disease. Due to the applicability of EBD analysis, this technique is actively being implemented to corroborate zebrafish models to the human disease state 11, 15, 22, 24, 32 . Larvae with damaged muscle membranes will have EBD uptake and therefore red fluorescence within muscle fibers. Fluorescence observed in the inter-fiber space, but not within individual muscle fibers may also be informative of fibers detaching from the basement membrane in the absence of membrane damage, providing useful diagnostic detail. EBD analysis has potential application beyond animal model validation. Efforts from our lab have recently demonstrated that EBD analysis is beneficial in validating potentially novel therapeutic drugs 24 . Determining if potential therapeutic treatments reduce or abolish EBD uptake in neuromuscular disease models can signify relevant therapeutic action 8 . This type of analysis can help establish the mechanism(s) of therapeutics and expands the application of EBD analysis.
As with many techniques, EBD analysis does have several caveats to be observed during experimental design and practice. For example, it can be challenging to identify the CCV due to the thickening of the tissue with age. Additionally, it is easy to damage larvae in preparation before and during the pericardial injection, reducing experimental counts and increasing the need to prep large numbers of larvae. Furthermore, physical damage done to the larvae during handling and injection could result in false positives as damaged muscle can take up EBD. In order to overcome some of these obstacles, we have described a co-injection strategy in this video article that allows easy and reliable identification of larvae with successful dye infusion immediately following injection and prior to subsequent analysis. The FITC-dextran co-injection controls for successful injection by allowing confirmation of EBD in the vasculature prior to its uptake by the muscle fibers. This can be particularly useful as EBD fluorescence becomes highly diffuse in larvae after several hours if not collected in the muscle fibers; as such, it can be difficult to detect. In addition, missing the CCV and injecting EBD into the yolk or body cavity can, after incubation, result in diffuse red fluorescence similar to control embryos, yet with the reduced likelihood of uptake by damaged muscle fibers. Collectively, these caveats suggest EBD injection requires patience and practice in order to achieve consistent and reliable results.
In all, we describe a practical and straightforward method to perform EBD analysis on zebrafish larvae. To date, the use of zebrafish as a model system, especially as a human disease model, has been rapidly expanding. This expansion is partially due to the continued development and modification of experimental techniques that improve upon the current advantages of the zebrafish system. The EBD injection technique provides an additional and powerful tool to a researcher's arsenal for the validation and study of zebrafish muscle disease models. The ongoing implementation and modification of this technique has the potential to help uncover novel therapeutic strategies as well as disease causing mechanisms.
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